Filtered By:
Vaccination: Veterinary Vaccinations

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 7225 results found since Jan 2013.

The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice
In this study, we evaluated an immunotherapy protocol in a murine model by combining recombinant (r)LiHyp1 (a hypothetical amastigote-specific Leishmania protein protective against Leishmania infantum infection), with monophosphoryl-lipid A (MPLA) as adjuvant and amphotericin B (AmpB) as reference antileishmanial drug. We used this protocol to treat L. infantum infected-BALB/c mice, and parasitological, immunological and toxicological evaluations were performed at 1 and 30 days after treatment. Results showed that mice treated with rLiHyp1/MPLA/AmpB presented the lowest parasite burden in all organs evaluated, when both a ...
Source: Acta Tropica - July 15, 2023 Category: Infectious Diseases Authors: Daniela P Lage V ívian T Martins Danniele L Vale Camila S Freitas Breno L Pimenta Gabriel J L Moreira Fernanda F Ramos Isabela A G Pereira Raquel S Bandeira Marcelo M de Jesus Fernanda Ludolf Grasiele S V Tavares Miguel A Ch ávez-Fumagalli Bruno M Roatt Source Type: research

Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies
Antiviral Res. 2023 Jul 12:105670. doi: 10.1016/j.antiviral.2023.105670. Online ahead of print.ABSTRACTThe hepatitis E virus (HEV) is a major cause of hepatitis, with an estimated 3.3 million symptomatic cases annually. There is no HEV-specific treatment besides the off-label use of ribavirin and a vaccine is only available in China and Pakistan. To aid the development of therapeutic and preventive strategies, there is a need for convenient HEV infection models in small laboratory animals. To this end, we make use of the rat hepatitis E virus. Human infections with this virus have been reported in recent years, making it a...
Source: Antiviral Research - July 14, 2023 Category: Virology Authors: Xin Zhang Niels Cremers Stijn Hendrickx Yannick Debing Tania Roskams Lotte Coelmont Johan Neyts Suzanne J F Kaptein Source Type: research

An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms
Eur J Med Chem. 2023 Jul 7;258:115629. doi: 10.1016/j.ejmech.2023.115629. Online ahead of print.ABSTRACTThe current Coronavirus Disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is highly contagious infection that breaks the healthcare systems of several countries worldwide. Till to date, no effective antiviral drugs against COVID-19 infection have reached the market, and some repurposed drugs and vaccines are prescribed for the treatment and prevention of this disease. The currently prescribed COVID-19 vaccines are less effective against the newly emergent varian...
Source: European Journal of Medicinal Chemistry - July 12, 2023 Category: Chemistry Authors: Biswanath Dinda Manikarna Dinda Subhajit Dinda Utpal Chandra De Source Type: research

PEI ‐PLGA nanoparticles significantly enhanced the immunogenicity of IsdB137‐361 proteins from Staphylococcus aureus
ConclusionThese data showed that PEI-PLGA nanoparticles can significantly enhance the immunogenicity of IsdB137-361 proteins, and provide an important reference for the development of novel immune adjuvant.
Source: Immunity, Inflammation and Disease - July 12, 2023 Category: Allergy & Immunology Authors: Beiyan Wang, Yazun Dong, Yuwei Cen, Shujie Chen, Xue Wen, Kaiyue Liu, Shuangshuang Wu, Liquan Yu, Yongzhong Yu, Zhanbo Zhu, Jinzhu Ma, Baifen Song, Yudong Cui Tags: ORIGINAL ARTICLE Source Type: research

rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
CONCLUSION: The rWTC-MBTA vaccine demonstrated efficacy in multiple animal models through T-cell mediated cytotoxicity and has potential as a therapeutic option for preventing and treating tumor metastasis with minimal systemic toxicity.PMID:37434263 | DOI:10.1186/s13046-023-02744-8
Source: Cell Research - July 11, 2023 Category: Cytology Authors: Juan Ye Herui Wang Rogelio Medina Samik Chakraborty Mitchell Sun Alex Valenzuela Xueyu Sang Yaping Zhang Ondrej Uher Jan Zenka Karel Pacak Zhengping Zhuang Source Type: research

Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy
Curr Microbiol. 2023 Jul 6;80(8):273. doi: 10.1007/s00284-023-03366-1.ABSTRACTThe emergence of SARS-CoV-2 and its variants have posed a significant threat to humankind in tackling the viral spread. Furthermore, currently repurposed drugs and frontline antiviral agents have failed to cure severe ongoing infections effectively. This insufficiency has fuelled research for potent and safe therapeutic agents to treat COVID-19. Nonetheless, various vaccine candidates have displayed a differential efficacy and need for repetitive dosing. The FDA-approved polyether ionophore veterinary antibiotic for treating coccidiosis has been ...
Source: Current Microbiology - July 6, 2023 Category: Microbiology Authors: Keerthana Gurukkalot Vinoth Rajendran Source Type: research

Specific mRNA lipid nanoparticles and acquired resistance to ticks
This study demonstrates that more than one I. scapularis target within 19ISP is required for resistance to ticks, and that additional targets may also play a role in this process.PMID:37407406 | DOI:10.1016/j.vaccine.2023.06.081
Source: Vaccine - July 5, 2023 Category: Allergy & Immunology Authors: Jaqueline Matias Yingjun Cui Xiaotian Tang Andaleeb Sajid Gunjan Arora Ming-Jie Wu Kathleen DePonte Hiromi Muramatsu Ying K Tam Sukanya Narasimhan Norbert Pardi Drew Weissman Erol Fikrig Source Type: research